Lynnette Henshaw is a pharmacist who is specialized in Oncology in Boston, Massachusetts. Patients can reach her at 850 Harrison Ave, Boston or contact her on 617-414-7356. Active license number of Lynnette Henshaw is PH239633 for Oncology in Massachusetts. Lynnette Henshaw is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Lynnette Henshaw speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Lynnette Henshaw
Specialization:
Oncology
Credentials:
PHARMD
Gender:
Female
Location:
850 Harrison Ave, Boston, Massachusetts, 02118-4001
Phone:
617-414-7356
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Lynnette Henshaw are as mentioned below.
NPI Number:
1538752555
NPI Enumeration Date:
19 Feb, 2021
NPI Last Update On:
19 Feb, 2021
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Lynnette Henshaw are as mentioned below.
Specialization
License Number
State
Status
Oncology
PH239633
Massachusetts
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
850 Harrison Ave Bsmt Suite, Boston, Massachusetts
Zip:
02118-4001
Phone Number:
617-414-7356
Fax Number:
--
Patients can reach Lynnette Henshaw at 850 Harrison Ave, Boston, Massachusetts or can call on phone at 617-414-7356.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 11 November, 2024.